Formulation and Process Optimization of Cinnarizine Fast-Release Tablets - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Formulation and Process Optimization of Cinnarizine Fast-Release Tablets
The authors prepared granules containing cinnarizine using polyethylene glycol 6000 as a melting binder and lactose monohydrate as hydrophilic filler. The effects of binder concentration and size were studied.

Pharmaceutical Technology
Volume 33, Issue 8, pp. 53-59

Materials and methods

Materials. CNZ was supplied by Rakshit DPL (Bombay, India). Lactose monohydrates and PEG 6000 were procured from S.D. Fine Chemicals (Mumbai, India). All chemicals and solvents used in this study were of analytical reagent grade. Freshly distilled water was used throughout the work.

Fluidized-bed melt granulation. CNZ, PEG, and lactose monohydrate were granulated in a fluidized-bed dryer. The unit consisted of a conical container with a fine-mesh nylon gauze air distributor, stainless-steel support gauze, and a filter bag at the top of the unit. In the granulation experiments, various temperatures (56, 60, 64, and 68 C) were used to melt the PEG. A temperature controller provided an accuracy of 1 C. The mean air speed was maintained at predetermined levels (350, 450, 550, and 650 m3/h). The 200-g formulations were co-melted and fluidized for predetermined periods (5, 10, 15, and 20 min). Because the granulation temperature exceeded the melting temperature of PEG, the granules were cooled and consolidated by fluidizing the granulate under ambient air for 30 s at the end of each granulation run. This experimental procedure ensured rapid crystallization of the PEG and is referred to as short isothermal crystallization time (ICT) (5).

Granule characterization. Differential scanning calorimetry (DSC) analysis. DSC scans of powdered samples from all of the ingredients individually and of the melt granules were recorded using a DSC- Shimadzu 60 instrument with TDA trend line software. All samples were weighed (8–10 mg) and heated at a scanning rate of 20 C/min under dry airflow (100 mL/min) between 50 and 300 C. Aluminum pans and lids were used for all samples.

Granule size and shape. A granule-size distribution study was performed with a vibrating sieve shaker (Kevin Engineering, Ahmedabad, India) (11). Granules' size, shape, and surface were characterized with a scanning electron microscope (SEM, Philips XL30 ESEM TMP, FEI, Hillsboro, OR).

Friability. A friability test was carried out with 10-g granules placed in a Roche friabilator (Campbell Electronics Mumbai, India) for 5 min at 25 rpm (11).

Drug content. Granules were dissolved in methanol. The drug content was determined with a UV spectrophotometer at 254 nm (Shimazdu-1601 UV–vis spectrophotometer, Shimadzu, Kyoto, Japan).

Ungranulated materials. The presence of powder materials that were not granulated may be attributed to insufficient binder concentration or fluidization. The materials were retained as ungranulated and weighted against total weight of materials.

Figure 2: Differential scanning calorimetry spectra of granules prepared with (a) melt granulation, (b) cinnarizine, (c) lactose monohydrate, (d) poly(ethylene glycol) 6000. (FIGURE IS COURTESY OF THE AUTHORS)
Dissolution study. Dissolution studies of all samples were performed with USP XXIII apparatus type 2. Granules equivalent to 25 mg of CNZ were added to the dissolution medium (900 mL of distilled water at 37 0.5 C), which was stirred with a rotating paddle at 50 rpm. At suitable time intervals, 10-mL samples were withdrawn, filtered (0.22 μm), diluted, and analyzed at 254 nm with the UV spectrophotometer. An equal volume of fresh medium prewarmed at the same temperature was replaced in the dissolution medium after each sampling to maintain its constant volume throughout the test. Each test was performed in triplicate, and calculated mean values of cumulative drug release were used while plotting the release curves (13).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here